DRUG
Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial
Status
Terminated
Phase
Phase 3
Enrollment
250
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of this trial is to determine whether bivalirudin is non-inferior to unfractionated heparin in patients with stable angina, unstable angina, or non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Interventions
Treatment arms and agents.
DRUG
Unfractionated heparin
Timeline
From registration to results.
First posted
May 19, 2015
Study start
May 2015
Primary completion
May 6, 2016
Study completion
Jun 16, 2016
Results posted
Not reported
Registry updated
May 24, 2018
Outcomes
What the study measures.
Primary outcomes
Net adverse clinical events (composite of efficacy and safety [bleeding] endpoints)
Time frame · 30-days
Secondary outcomes
all cause mortality, myocardial infarction, or unplanned revascularization for ischemia
Time frame · 30-days
Bleeding Academic Research Consortium grade III or V bleeding events
Time frame · 30-days
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: 1. Undergoing PCI for stable angina, unstable angina, or non-ST segment elevation myocardial infarction. 2. Age 18 years or older. Exclusion Criteria: 1. Inability to obtain consent 2. Emergency cardiac catheterization for ST-segment elevation myocardial infarction.
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Bivalirudin.
NCT IDStudyPhase / statusEnrollmentUpdated
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Duke University · Coronavirus Infection (COVID-19) · Pulmonary Arterial Hypertension
Not applicable
Recruiting
5,000
2026-07
BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation
Sydney Local Health District · Extracorporeal Membrane Oxygenation Complication
Phase 2
Recruiting
80
2026-05
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
Xiaotong Hou · Extracorporeal Membrane Oxygenation Complication
Not applicable
Recruiting
154
2026-04
Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes
Shenyang Northern Hospital · Percutaneous Coronary Intervention · High Bleeding Risk
Phase 4
Not yet recruiting
5,270
2026-02
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
Stanford University · Heart Failure · Cardiogenic Shock
Phase 2
Recruiting
50
2026-01
A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
NYU Langone Health · Coronary Microvascular Disease · Ischemic Heart Disease
Not applicable
Active, not recruiting
206
2025-11
Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI
Shenyang Northern Hospital · ST Elevation Myocardial Infarction
Not applicable
Completed
6,016
2025-08
A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.
Peking University First Hospital · Coronary Microvascular Dysfunction
Phase 4
Recruiting
70
2025-08
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.